Home › Research › Health systems and care delivery
Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review
Xing Bingke, Yang Jingran, Hua Hui, Jiang Rong. Medicine, 2025-06-09
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This study evaluates the efficacy, safety, and economics of galantamine in the treatment of Alzheimer disease (AD) patients, and to provide evidence-based reference for optimizing drug selection, dosing strategies, and reimbursement policies in clinical practice. We used galantamine, systematic review, cost, and their synonym as keywords. The PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Weipu, Wanfang database, and Health Technology Assessment organization websites were searched to retrieve studies regarding galantamine for the treatment of AD from database creation to September 20, 2023. We extracted information and pooled the results of the studies for qualitative analyses instead of quantitative meta-analysis. This study incorporated 39 reports. Regarding effectiveness, galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning of the AD patients compared with the placebo. However, based on available data, it was not possible to infer whether galantamine was more effective than the other acetylcholinesterase inhibitor drugs. AD patients treated with galantamine showed a higher incidence of adverse gastrointestinal effects compared to those treated with placebo. Galantamine showed a higher incidence of adverse gastrointestinal effects than donepezil but a lower rate than rivastigmine. Regarding economics, compared with the placebo and non-pharmacological treatments, galantamine prolonged the duration of full-time care and in some cases even reduced the overall cost of galantamine use. Galantamine showed good efficacy, cost-effectiveness, and mild adverse effects in the treatment of patients with AD by prolonging the duration of full-time care and saving the cost compared with the placebo and non-pharmacological.
What this study adds
Evidence grade: High
This is a pooled review. Galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning compared with placebo in the reviewed studies. It caused more gastrointestinal side effects than placebo, and the review could not determine whether it was more effective than other acetylcholinesterase inhibitor drugs.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bingke, X., Jingran, Y., Hui, H., & Rong, J. (2025). Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review. Medicine. https://doi.org/10.1097/MD.0000000000042744
Vancouver
Bingke X, Jingran Y, Hui H, Rong J. Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review. Medicine. 2025. doi:10.1097/MD.0000000000042744. PMID: 40489822.
BibTeX
@article{bingke2025-40489822,
author = {Bingke, Xing and Jingran, Yang and Hui, Hua and Rong, Jiang},
title = {{Rapid health technology assessment of galantamine for the treatment of Alzheimer's disease: A review}},
journal = {Medicine},
year = {2025},
doi = {10.1097/MD.0000000000042744},
pmid = {40489822},
url = {https://doi.org/10.1097/MD.0000000000042744}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- We extracted information and pooled the results of the studies for qualitative analyses instead of quantitative meta-analysis.
- Regarding effectiveness, galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning of the AD patients compared with the placebo.
- AD patients treated with galantamine showed a higher incidence of adverse gastrointestinal effects compared to those treated with placebo.
- Galantamine showed a higher incidence of adverse gastrointestinal effects than donepezil but a lower rate than rivastigmine.
- Regarding economics, compared with the placebo and non-pharmacological treatments, galantamine prolonged the duration of full-time care and in some cases even reduced the overall cost of galantamine use.
Why it matters
Galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning compared with placebo in the reviewed studies. It caused more gastrointestinal side effects than placebo, and the review could not determine whether it was more effective than other acetylcholinesterase inhibitor drugs.
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 52/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 50 of the 96 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Medicine) |
| Journal's citation record | 3 / 4 | Medicine: journal h-index 285 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Rong Jiang holds only 6 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | China Pharmaceutical University: institution h-index 336 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40489822) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 50 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 50 of the 96 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.